The company focuses on developing a first-in-class companion biomarker and an innovative therapy to prevent the progression of neurodegeneration in its pre-symptomatic phase. T

he successful candidate will be part of the drug discovery team primarily performing ex-vivo screening studies using the Western Blot technique: she/he will therefore be expected to have general laboratory familiarity as well as experience of antibody-based detection systems.

Good presentation and IT skills as well as the ability to work well in a team are also required.

Start date 1st October 2017, or as soon as possible thereafter.

Salary to be negotiated.

Further background information on Neuro-Bio can be obtained from the website above or from Prof. Susan Greenfield CEO (susan.greenfield@neuro-bio.com).

Please send applications including a CV and the names of 2 referees to Julie Peachey (Julie.peachey@neuro-bio.com) by Monday August 21st.

Short-listed candidates will be contacted for a Skype or personal interview by the end of August.